---
layout: post
title: "回撤30%大反弹 机构紧握这一主线！8股业绩高增长 注意了！下周42股面临解禁"
date: 2022-02-26 08:20:02 +0800
categories: emnews
tags: 东财滚动新闻
---
> 医药板块从2021年10月以来一直表现较低迷，指数累计回撤幅度高达30%左右，昨日板块集体大爆发。统计显示，药石科技、长春高新、贝达药业等8股的股价年内累计跌超20%。与2021年的股价高点相比，包含康希诺-U、甘李药业、康弘药业、长春高新、康泰生物、恒瑞医药在内的15股的股价已经跌超50%。（数据宝）

<p>医药板块从2021年10月以来一直表现较低迷，指数累计回撤幅度高达30%左右，昨日板块集体大爆发。</p><p><strong>超百只医药股获<span id="Info.3221"><a href="http://data.eastmoney.com/jgdy/" class="infokey">机构调研</a></span></strong></p><p><span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>发布<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>快报表示，2021年归母<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>盈利5.57亿元，同比增长76.83%，该数据高于市场预期，此前机构<span id="Info.3224"><a href="http://data.eastmoney.com/invest/invest/default.html" class="infokey">分析师</a></span>普遍预期该公司2021年净利润盈利近5亿元左右。<strong>受业绩利好刺激，<span web="1" href="http://quote.eastmoney.com/unify/r/1.603127" class="em_stock_key_common" data-code="1,603127">昭衍新药</span>昨日股价大涨8.18%，最新市值407.45亿元。</strong></p><p style="display:none;height:1px;overflow:hidden;"> </p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.603127&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 603127_0" data-code="K 603127|1|1" data-code2="K 603127|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><center></center><p>实际上昨日盘面最大亮点是医药股，集体大反弹，涨幅靠前的概念几乎被医药包圆，包括CRO、体外诊断、新冠检测、新冠药物、精准医疗、基因测序等等。<span id="stock_0.002644"><a href="http://quote.eastmoney.com/unify/r/0.002644" class="keytip" data-code="0,002644">佛慈制药</a></span><span id="quote_0.002644"></span>3连板，<span id="stock_0.301201"><a href="http://quote.eastmoney.com/unify/r/0.301201" class="keytip" data-code="0,301201">诚达药业</a></span><span id="quote_0.301201"></span>、<span id="stock_0.002433"><a href="http://quote.eastmoney.com/unify/r/0.002433" class="keytip" data-code="0,002433">太安堂</a></span><span id="quote_0.002433"></span>收获涨停板。</p><center><img src="https://dfscdn.dfcfw.com/download/D25408438182982541554_w1080h1937.jpg" alt="Image" width="412" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>医药板块从2021年10月以来一直表现较低迷，多个概念指数呈现震荡下行的行情，指数累计回撤幅度高达30%左右。</strong>昨日板块集体大爆发，一方面是随着大盘系统性修复，医药板块迎来修复；另一方面，据国家药监局药审中心网站消息，为鼓励研究和创制新药，加快创新药品的审评速度，国家药监局药品审评中心近日就《药审中心加快创新药上市申请审评工作程序(试行)(征求意见稿)》公开征求意见。</p><p>随着医药股的反弹，市场众多机构也开始纷纷唱多。医药板块经过调整，目前已经进入布局中长期价值区间，尤其是一些龙头公司在经历无差别暴跌后，估值已经颇具优势。集采政策、外围等悲观情绪逐步消化，板块后市投资机会向好。近期发布的《“十四五”医药工业发展规划》，指出医药工业<span id="Info.3323"><a href="http://data.eastmoney.com/bbsj/" class="infokey">营业收入</a></span>、利润总额年均增速保持在8%以上，增加值占全部工业的比重提高到5%左右，行业龙头企业集中度进一步提高。</p><p><strong>统计显示，创新药指数46只成份股中，仅有<span id="stock_0.300841"><a href="http://quote.eastmoney.com/unify/r/0.300841" class="keytip" data-code="0,300841">康华生物</a></span><span id="quote_0.300841"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603127" class="em_stock_key_common" data-code="1,603127">昭衍新药</span>、<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_1.603858"><a href="http://quote.eastmoney.com/unify/r/1.603858" class="keytip" data-code="1,603858">步长制药</a></span><span id="quote_1.603858"></span>4只股的年内累计上涨幅度录得正值。</strong><span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>、<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>、<span id="stock_0.300558"><a href="http://quote.eastmoney.com/unify/r/0.300558" class="keytip" data-code="0,300558">贝达药业</a></span><span id="quote_0.300558"></span>等8股的股价年内累计跌超20%。与2021年的股价高点相比，包含<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺-U</a></span><span id="quote_1.688185"></span>、<span id="stock_1.603087"><a href="http://quote.eastmoney.com/unify/r/1.603087" class="keytip" data-code="1,603087">甘李药业</a></span><span id="quote_1.603087"></span>、<span id="stock_0.002773"><a href="http://quote.eastmoney.com/unify/r/0.002773" class="keytip" data-code="0,002773">康弘药业</a></span><span id="quote_0.002773"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000661" class="em_stock_key_common" data-code="0,000661">长春高新</span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>在内的15股的股价已经跌超50%。</p><p>股价低迷，但却丝毫不影响机构对于医药股的关注，根据申万行业分类，新年以来，421家A股医药公司中，共有103家医药公司接受了机构<span id="Info.3274"><a href="http://data.eastmoney.com/jgdy/" class="infokey">调研</a></span>。去年全年机构共调研262家医药公司，而新年仅两个月，机构调研数量已达去年一半。<strong>创新药概念股中，<span id="stock_0.000963"><a href="http://quote.eastmoney.com/unify/r/0.000963" class="keytip" data-code="0,000963">华东医药</a></span><span id="quote_0.000963"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000661" class="em_stock_key_common" data-code="0,000661">长春高新</span>、<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>、<span id="stock_1.600380"><a href="http://quote.eastmoney.com/unify/r/1.600380" class="keytip" data-code="1,600380">健康元</a></span><span id="quote_1.600380"></span>的机构调研家数已超百家，<span web="1" href="http://quote.eastmoney.com/unify/r/0.000963" class="em_stock_key_common" data-code="0,000963">华东医药</span>的机构调研家数最多，达到482家。</strong></p><p>从业绩预告下限数据和业绩快报来看，27只创新药概念股的2021年业绩实现盈利且同比呈现增长。<span id="stock_0.002294"><a href="http://quote.eastmoney.com/unify/r/0.002294" class="keytip" data-code="0,002294">信立泰</a></span><span id="quote_0.002294"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688185" class="em_stock_key_common" data-code="1,688185">康希诺-U</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002773" class="em_stock_key_common" data-code="0,002773">康弘药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300725" class="em_stock_key_common" data-code="0,300725">药石科技</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688202" class="em_stock_key_common" data-code="1,688202">美迪西</span>、<span id="stock_1.688177"><a href="http://quote.eastmoney.com/unify/r/1.688177" class="keytip" data-code="1,688177">百奥泰-U</a></span><span id="quote_1.688177"></span>、<span id="stock_1.600535"><a href="http://quote.eastmoney.com/unify/r/1.600535" class="keytip" data-code="1,600535">天士力</a></span><span id="quote_1.600535"></span>8股的业绩呈现翻倍增长。</p><center><img src="https://dfscdn.dfcfw.com/download/D25254400653927488621_w1080h1158.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>42股下周面临解禁</strong></p><p><strong>下周将有42只股解禁，按照最新收盘价计算，合计解禁市值372.55亿元。</strong></p><p>解禁规模最大的是<span id="stock_1.688696"><a href="http://quote.eastmoney.com/unify/r/1.688696" class="keytip" data-code="1,688696">极米科技</a></span><span id="quote_1.688696"></span>，下周将有0.21亿股上市流通，主要是首发原<span id="Info.3286"><a href="http://data.eastmoney.com/gdfx/" class="infokey">股东</a></span><span id="Info.324"><a href="http://data.eastmoney.com/dxf/default.html" class="infokey">限售股</a></span>份和首发战略配售股份，解禁市值达99.73亿元。</p><p>从<span id="Info.325"><a href="http://data.eastmoney.com/dxf/default.html" class="infokey">解禁股</a></span>数量占总股本的比例来看，<span id="stock_0.002949"><a href="http://quote.eastmoney.com/unify/r/0.002949" class="keytip" data-code="0,002949">华阳国际</a></span><span id="quote_0.002949"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688696" class="em_stock_key_common" data-code="1,688696">极米科技</span>、<span id="stock_1.600928"><a href="http://quote.eastmoney.com/unify/r/1.600928" class="keytip" data-code="1,600928">西安银行</a></span><span id="quote_1.600928"></span>、<span id="stock_1.688677"><a href="http://quote.eastmoney.com/unify/r/1.688677" class="keytip" data-code="1,688677">海泰新光</a></span><span id="quote_1.688677"></span>、<span id="stock_1.688569"><a href="http://quote.eastmoney.com/unify/r/1.688569" class="keytip" data-code="1,688569">铁科轨道</a></span><span id="quote_1.688569"></span>等股的解禁比例居前，但均未超过50%。</p><p>数据宝统计显示，下周将要解禁的这42只股票，自1月以来股价平均下跌9.92%，跑输同期大盘。<span id="stock_0.300949"><a href="http://quote.eastmoney.com/unify/r/0.300949" class="keytip" data-code="0,300949">奥雅设计</a></span><span id="quote_0.300949"></span>、<span id="stock_1.688086"><a href="http://quote.eastmoney.com/unify/r/1.688086" class="keytip" data-code="1,688086">紫晶存储</a></span><span id="quote_1.688086"></span>、<span id="stock_1.688378"><a href="http://quote.eastmoney.com/unify/r/1.688378" class="keytip" data-code="1,688378">奥来德</a></span><span id="quote_1.688378"></span>、<span id="stock_1.601968"><a href="http://quote.eastmoney.com/unify/r/1.601968" class="keytip" data-code="1,601968">宝钢包装</a></span><span id="quote_1.601968"></span>、<span id="stock_1.603882"><a href="http://quote.eastmoney.com/unify/r/1.603882" class="keytip" data-code="1,603882">金域医学</a></span><span id="quote_1.603882"></span>等10股的股价今年以来累计跌幅超20%。</p><p>目前28股已经发布了2021年业绩预告或快报。根据预告中值或快报来看，<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>的盈利最高，公司快报显示2021年实现营业收入约229.02亿元，同比增长38.5%；实现归母净利润约50.97亿元，同比增长72.19%。</p><p><span id="stock_1.689009"><a href="http://quote.eastmoney.com/unify/r/1.689009" class="keytip" data-code="1,689009">九号公司-WD</a></span><span id="quote_1.689009"></span>、<span id="stock_1.601969"><a href="http://quote.eastmoney.com/unify/r/1.601969" class="keytip" data-code="1,601969">海南矿业</a></span><span id="quote_1.601969"></span>、<span id="stock_1.688711"><a href="http://quote.eastmoney.com/unify/r/1.688711" class="keytip" data-code="1,688711">宏微科技</a></span><span id="quote_1.688711"></span>、<span id="stock_0.300706"><a href="http://quote.eastmoney.com/unify/r/0.300706" class="keytip" data-code="0,300706">阿石创</a></span><span id="quote_0.300706"></span>、<span id="stock_1.688396"><a href="http://quote.eastmoney.com/unify/r/1.688396" class="keytip" data-code="1,688396">华润微</a></span><span id="quote_1.688396"></span>、<span id="stock_0.002858"><a href="http://quote.eastmoney.com/unify/r/0.002858" class="keytip" data-code="0,002858">力盛赛车</a></span><span id="quote_0.002858"></span>的2021年业绩预计将呈现同比翻倍上涨。</p><center><img src="https://dfscdn.dfcfw.com/download/D25339146436183628588_w1080h1696.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：数据宝）</p>

<http://finance.eastmoney.com/news/11158,202202262290186477.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)